The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Sucampo Pharmaceuticals whiffed on revenue and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped significantly and GAAP earnings per share increased.
Gross margin contracted, operating margin dropped, and net margin improved.
Sucampo Pharmaceuticals reported revenue of $12.4 million. The one analyst polled by S&P Capital IQ expected to see sales of $15.5 million on the same basis. GAAP reported sales were 15% higher than the prior-year quarter's $12.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at -$0.15. The one earnings estimate compiled by S&P Capital IQ averaged -$0.01 per share on the same basis. GAAP EPS were $0.06 for Q4 versus -$0.07 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 46.1%, 4,620 basis points worse than the prior-year quarter. Operating margin was -52.7%, 4,410 basis points worse than the prior-year quarter. Net margin was 19.0%, 4,240 basis points better than the prior-year quarter.
Next year's average estimate for revenue is $55.0 million.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 62 members out of 72 rating the stock outperform, and 10 members rating it underperform. Among 15 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 13 give Sucampo Pharmaceuticals a green thumbs-up, and two give it a red thumbs-down.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Sucampo Pharmaceuticals the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Sucampo Pharmaceuticals to My Watchlist.